Milestone Scientific Yönetim

Yönetim kriter kontrolleri 2/4

Milestone Scientific CEO'su Neil Goldman, Dec2024 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 2.45% doğrudan sahiptir ve bu hisselerin değeri $ 2.40M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.1 yıl ve 4.3 yıldır.

Anahtar bilgiler

Neil Goldman

İcra Kurulu Başkanı

US$120.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	2.4%
Yönetim ortalama görev süresi	1.1yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Feb 23

Here's What Milestone Scientific Inc.'s (NYSEMKT:MLSS) Shareholder Ownership Structure Looks Like

Dec 15

CEO

Neil Goldman (80 yo)

less than a year

Görev süresi

US$120,000

Tazminat

Mr. Neal Ira Goldman, CFA, also known as Neil, has been the Interim Chief Executive Officer of Milestone Scientific Inc. since December 31, 2024. He has been an Independent Director of Milestone Scientific...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Neal Goldman	Chairman of the Board & Interim CEO	less than a year	US$120.00k	2.45% $ 2.4m
Leonard Osser	Founder & Vice Chairman	33.6yrs	US$100.00k	3.49% $ 3.4m
Jan Haverhals	President & Director	4.4yrs	US$680.27k	Veri yok
James Hippett	Senior VP of Global Sales & Business Development	1.1yrs	Veri yok	Veri yok
Keisha Harcum	Controller	no data	Veri yok	Veri yok

1.1yrs

Ortalama Görev Süresi

77yo

Ortalama Yaş

Deneyimli Yönetim: MLSS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.1 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Neal Goldman	Chairman of the Board & Interim CEO	5.8yrs	US$120.00k	2.45% $ 2.4m
Leonard Osser	Founder & Vice Chairman	33.6yrs	US$100.00k	3.49% $ 3.4m
Jan Haverhals	President & Director	2.1yrs	US$680.27k	Veri yok
Paul Davis	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Benedetta Casamento	Independent Director	2.8yrs	US$120.00k	0.52% $ 509.7k
Ralf Gebhard	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Lorrence Green	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Michael McGeehan	Independent Director	7.3yrs	US$110.00k	0.74% $ 724.8k
Olivier Choquet	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Didier Demesmin	Independent Director	1.4yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MLSS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/02 21:11
Gün Sonu Hisse Fiyatı	2025/01/31 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Milestone Scientific Inc. 6 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Bruce Jackson	Benchmark Company
Anthony Vendetti	Maxim Group
Jon Hickman	MDB Capital Group LLC

Milestone Scientific Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Milestone Scientific Inc. Announces CEO Changes

Founder & Vice Chairman recently sold US$135k worth of stock

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Recent updates

Consensus EPS estimates fall by 25%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Milestone Scientific Inc. Announces CEO Changes

Milestone Scientific Expands Commercial Rollout of the CompuFlo Epidural System with Esteemed Pain Management Physician Dr. Elbaz At Hudson Specialty Care

Milestone Scientific Inc. Announces Commercial Rollout of Compuflo® Epidural System At Iheal Pain Center Following Medicare Price Assignment

Founder & Vice Chairman recently sold US$135k worth of stock

Second quarter 2024 earnings released: EPS: US$0.003 (vs US$0.031 loss in 2Q 2023)

Milestone Scientific Inc. Secures Key Patent Approvals in the U.S. and Europe

Milestone Scientific Announces Medicare Price Assignment for the CompuFlo® Epidural System in Texas, Pennsylvania, New Jersey, Maryland, Colorado, Oklahoma, Louisiana, Arkansas, Mississippi, New Mexico, District of Columbia, and Delaware

Milestone Scientific Inc. Announces Favorable Medicare Pricing for Its CompuFlo® Epidural System Within First JMAC Region Covering Florida

Milestone Scientific Receives Regulatory Approval to Market Compuflo Epidural System in Brazil

Milestone Scientific Inc., Annual General Meeting, Jul 16, 2024

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Milestone Scientific Inc. has completed a Follow-on Equity Offering in the amount of $3.00195 million.

New minor risk - Shareholder dilution

Milestone Scientific Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 13%

New major risk - Financial position

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Director notifies of intention to sell stock

Less than half of directors are independent

Milestone Scientific Inc. Appoints Didier Demesmin to Board of Directors

Milestone Scientific Inc. Announces Resignation of Peter J. Milligan as Chief Financial Officer, Effective September 1, 2023

Consensus EPS estimates fall by 29%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Consensus estimates of losses per share improve by 12%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Milestone Scientific Inc. Announces the Appointment of Peter Milligan as the Chief Financial Officer

Milestone Scientific Inc. Announces Board Changes

Milestone Scientific Inc. Appoints Neal Goldman as Chairman of the Board of Directors

Leonard M. Schiller Tenders His Resignation to Milestone Scientific Inc. as A Director

Insufficient new directors

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Milestone Scientific Inc. Reports Commencement of Sales of its CompuFlo(R) Epidural Instrument Disposables at a Leading Veterinary and Academic Institution

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Insufficient new directors

Milestone Scientific Inc., Annual General Meeting, Jun 13, 2022

Price target decreased to US$4.00

Price target decreased to US$4.00

Founder notifies of intention to sell stock

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Founder notifies of intention to sell stock

Milestone Scientific Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Founder exercised options to buy US$268k worth of stock.

Third quarter 2021 earnings released: US$0.029 loss per share (vs US$0.023 loss in 3Q 2020)

Founder exercised options to buy US$417k worth of stock.

Independent Chairman of the Board notifies of intention to sell stock

Independent Chairman of the Board recently sold US$86k worth of stock

Consensus EPS estimates fall to -US$0.11

Second quarter 2021 earnings released: US$0.039 loss per share (vs US$0.056 loss in 2Q 2020)

Chief Financial Officer Scott Kahn has left the company

Milestone Scientific Inc.(NYSEAM:MLSS) dropped from Russell 3000E Value Index

Consensus forecasts updated

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.032 loss in 1Q 2020)

Consensus revenue estimates increase to US$10.3m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.17 loss in FY 2019)

Milestone Scientific Receives Notice of Allowance for European Patent Related to Combination of Nerve Stimulation and Dps Dynamic Pressure Sensing Technology® to Optimize Needle Tip Location in Ultrasound-Guided Pnb Procedures

Milestone Scientific Inc. Commences Sales of CompuFlo® / CathCheck™ Disposables to the Nationally Recognized Medical University of South Carolina

New 90-day high: US$4.13

Did You Miss Milestone Scientific's (NYSEMKT:MLSS) Whopping 317% Share Price Gain?

Independent Chairman of the Board notifies of intention to sell stock

Analysts update estimates

Independent Chairman of the Board recently sold US$169k worth of stock